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Abstract
Background: Cytokines play important roles in antiviral action. We examined whether polymorphisms of interleukin (IL)-12
receptor B1( IL-12RB1) affect the susceptibility to and outcome of severe acute respiratory syndrome (SARS).
Methods: A case-control study was carried out in Chinese SARS patients and healthy controls. The genotypes of 4SNPs on
IL-12 RB1 gene, +705A/G,+1158T/C, +1196G/C and +1664 C/T, were determined by PCR-RFLP. Haplotypes were estimated
from the genotype data using the expectation-maximisation algorithm.
Results: Comparison between patients and close contacts showed that individuals with the +1664 C/T (CT and TT) genotype
had a 2.09-fold (95% confidence interval [CI], 1.90–7.16) and 2.34-fold (95% CI, 1.79–13.37) increased risk of developing
SARS, respectively. For any of the other three polymorphisms, however, no significant difference can be detected in allele or
genotype frequencies between patients and controls. Additionally, estimation of the frequencies of multiple-locus
haplotypes revealed potential risk haplotypes (GCCT) for SARS infection.
Conclusions: Our data indicate that genetic variants of IL12RB1confer genetic susceptibility to SARS infection, but not
necessary associated with the progression of the disease in Chinese population.
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Introduction
Severe acute respiratory syndrome (SARS) is an infectious
disease caused by the SARS coronavirus with .8000 cases and
774 deaths reported in 2003 [1]. Much progress has been made in
understanding the SARS coronavirus, but its pathogenesis in
infected individuals remains unclear [2]. The early reports showed
that old age, diabetes mellitus and heart disease were risk factors
for adverse prognosis of SARS [3,4]. Genetic host factors are as
well supposed to play an important role, and polymorphisms in
several genes have been tested for their association with the
infection [5–13]. Three studies have investigated role of
angiotensin converting enzyme gene in disease pathogenesis or
disease outcome with conflicting results [5–7]. Two independent
studies displayed the significant role of the mannose-binding lectin
(MBL) genetic polymorphisms in SARS infection [8,9]. Other
candidate genes, such as OAS1 and MxA gene [10], interferon
gamma gene [11] and RANTES gene [12], ICAM3 gene [13]
were also identified in recent studies. A better understanding of
these genes will provide new insights into the disease pathogenesis.
This knowledge will also aid in identifying the biomarkers for
evaluating the efficacy of vaccination and other interventions.
Interleukin-12 (IL-12) is a cytokine secreted by activated
phagocytes and dendritic cells [14]. It plays a pivotal role in
promoting Th1-type immune responses and cell-mediated immu-
nity. IL-12 triggers many biological functions: it stimulates the
proliferation of activated T- and NK-cells, enhances T- and NK-
cell-mediated cytolytic activity, and induces the production of
IFN-c by both T-and NK-cells (Trinchieri 1998). The interferon-c
production induced by IL-12 forms a major link between innate
and adaptive immunity [15]. A recent study revealed that
interferon-mediated immunopathological events are associated
with atypical innate and adaptive immune responses in SARS
patients [16]. We thus reasoned that IL-12 might also play a role
in resistance to SARS, which is signaled through the direct binding
of the IL-12 molecule to its receptor (IL- 12R). IL-12R has been
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associate to form a high-affinity IL-12R complex expressed on
activated T- and NK-cells (17,18). In the current study, we
hypothesized that polymorphisms of the IL-12R B1 gene might be
associated with SARS susceptibility. To test this hypothesis, we
conducted a case control study to investigate the association




The case and controls were selected from two designated
hospitals for SARS in Beijing and Tianjin. During the 2003 SARS
epidemic, a total of 132 confirmed SARS patients were reported
from these two hospitals, which derived from two completely
unrelated super spread events (SSE). All of the patients had been
hospitalized for treatment, from which we selected 115 confirmed
SARS cases for the study. Three of the remaining patients died
and the other 14 patients were unavailable for study, because of
the inconvenience of revisiting. The diagnosis was made according
to the criteria published by the Chinese Ministry of Public Health,
and subsequently confirmed by antibody seroconversion and/or
detectable SARS-CoV RNA in respiratory secretions. Two control
groups were used, individuals with close contacts with SARS
patients (control A) and healthy controls (control B). Control A
group consists of 141 subjects who had close contacts with
confirmed SARS patients but were not infected, according to
criteria that was defined by the World Health Organization [19].
Among these individuals were 110 high-risk health care workers
who had been treating SARS patients for a prolonged duration,
and 31 individuals who had shared a meal, utensil, residence,
ward, vehicle, etc., with SARS patients. Control B group included
155 healthy, unrelated Chinese blood donors, who had blood
drawn during July 2001–October 2002. All controls were tested
negative for IgG antibody against SARS-CoV prior to being
included into the study. All subjects contributed 3ml anti-
coagulated blood after written informed consent was obtained.
We also used a standard questionnaire to collect demographic
information (including age, ethnicity, region of origin, marital
status, living environment, education level et al). All subjects were
confirmed as genetically unrelated through interviewing. The
comorbidity conditions that might have effect on disease
susceptibility, such as diabetes mellitus, heart disease, hyperten-
sion, asthma, tuberculosis, and malignancy, were traced by
reviewing medical records and self reporting. The study protocol
was approved by the ethical committee at the National Center for
AIDS Prevention and Control.
IL-12R B1 Genotyping Using PCR-RFLP
Leucocytes were isolated within 12 h of blood collection using
Percoll reagent. Genomic DNA was extracted using cell DNA
extraction kit (BioDEV Inc. Beijing, China) following the
manufacturer’s instructions.
We typed the samples for 4 previously reported SNPs that cause
missense mutations in the coding sequence of the IL-12RB1 gene
[20] , namely +705A/G (Q214R, NCBI SNP ID:rs 11575934),
+1158T/C(M365T, NCBI SNP ID:mrs 375947), +1196G/C
(G378R, NCBI SNP ID: rs 401502), and +1664 C/T (P534S,
HGBASE database ID: SNP001745641). For +705A/G genotyp-
ing, genomic DNA was amplified using the primer set 59-
ggttaagtgactggtgccaag-39 and 59- ctcaaaccactggcctcaag-39. The
PCR fragment obtained was restricted with Bbv I (New England
BioLabs, Beverly, Mass., US) at 37uC. For +1158T/C typing
(M365T), 59-aacaaacgccatctgctacc-39 and 59-caacacctctctgggcctta-
3 9, and Hsp 92II (Promega, Madison, Wisc., USA) were used at
37uC. For +1196G/C, 59 -aacaaacgccatctgctacc-3 9 and 59-
agagtgagaggccacctgag-3 9 , and Msp I (Promega, Madison, Wisc.,
USA) were used at 37uC. For +1664 C/T, 59-ggctgtggtagcccagcct-
39 and 59-ggaagcgcagtgcagtgcatg-39 were used and restricted with
Bsr I (New England BioLabs) at 65uC. PCR was carried out in
PCR buffer (1.5 m M MgCl 2 , 10 m M Tris-HCl, pH 9.0, 50 m
M KCl, 0.1% Triton H X-100), 100 mM of each dNTP, 25 mM
primers and 1 unit of Taq polymerase in a final volume of 30 ml.
Following an initial denaturation at 95uC for 5 min, samples were
subjected to 30 cycles of PCR amplification with denaturation at
95uC for 30 s, annealing at 57–60uC for 30 s and elongation at
72uC for 30 s, followed by a final elongation step at 72uC for
10 min. The reaction products of the PCRs and enzyme
restrictions were analyzed on 3% agarose gels (+705A/G,
+1158T/C, +1664 C/T) or 8% polyacrylamide gels (+1196G/
C). The genotyping of all samples were performed in a blinded
manner so that the case or control status was not known. Ten
percent of the samples were chosen randomly from each
polymorphism for resequencing in order to validate the genotyp-
ing method.
Statistical analysis
Genotype distributions of each SNPs were tested for the Hardy–
Weinberg equilibrium by the Chi square test in three groups. The
genotype frequencies of the SARS patients and the control
subjects were compared, and odds ratios (OR) were calculated
by assigning the reference value (1.0) to the homozygous genotype
that was more frequent in the control subjects than in the SARS
patients. The OR and P values were calculated by multivariate
logistic regression analysis with age, sex , comorbidity presence
and infection source entered as covariates in the model, given
the relevance of these potential confounding variables in
interpreting the study results. Data were analyzed using the SPSS
software (version 10.0, SPSS Inc, Chicago, IL, USA). To correct
for multiple testing, we used spectral decomposition (SpD) of
matrices of pairwise linkage disequilibrium (LD) between SNPs,
which adjusts for multiple testing while taking into account
LD among the tested SNPs [21]. This method showed that
P-values of 0.0227 and below can be considered as statistically
significant after correction for multiple testing. The software
HAPLOVIEW (version 2.05) was used to construct haplotypes
from the genotype data. This program calculates association
statistics for multilocus haplotypes in case-control data using the
expectation- maximisation algorithm to estimate haplotype odds
ratios across multiple categories, giving a likelihood ratio test of
homogeneity.
Results
Baseline Clinical Characteristics of cases and controls
Table 1 shows the baseline characteristics of SARS patients and
two control groups. The mean age was 33.1611.7 years for SARS
cases, 31.667.0 years for control A group and 28.4611.8 years
for control B group. 46.7% of SARS patients, 32.5% of control A
group and 71% of control B group were male. Sixty-two SARS
patients were health care workers. Thirty-nine (33.9%) patients
were classified as a severe group, based on their admissions to
intensive care units or deaths due to the disease (mean6SD
age=39.45612.8, 20 male and 19 female). The remaining 76
patients were classified as a mild group (mean6SD
age=29.61613.5, 46 male and 56 female).
IL12 and SARS
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in SARS Patients and Controls
The Hardy-Weinberg equilibrium test based on the genotype
frequency was carried out separately for the three groups of
individuals. For control B group, the genotype distributions of the
4 SNPs (+705A/G, +1158T/C, +1196G/C and +1664 C/T) were
in Hardy-Weinberg equilibrium, while for patients group, the
genotype distribution of +1664 C/T polymorphisms deviate
slightly from Hardy-Weinberg equilibrium (data not shown).
The genotyping results were missing from some of the patients,
because the DNA samples were not enough for all of the loci
detection, or the poor RFLP results, which led to their exclusion
from the analysis. Allele frequencies at the four loci were
compared (Table 2). +1664 C/T (T) allele is shown to be
overrepresented in the group of patients, when compared with
those in the control A group (P-value 0.044) and control B group
(P-value 0.056). However, when the Nyholt correction was applied
in the screening step, the P values turned out to be not significant.
The allele frequencies of the other three SNPs (+705A/G,
+1158T/C, +1196 G/C) were not significantly different between
SARS patients and any of the two control groups, with all the P
value to be great than 0.05.
Genotype frequencies at four loci are shown in Table 3. A
significant difference in the genotype frequencies between SARS
patients and controls was found for the +1664 C/T SNPs
(P,0.001). The +1664 C/T (CT) and (TT) genotypes were
significantly over represented in patients (41.5% and 8.5%,
respectively) than in control A group (29.5% and 4.5%,
respectively). Compared to the CC genotype, CT and TT
genotypes were found to be associated with increased susceptibility
to SARS infection with ORs (95% CI) of 2.09 (1.90–7.16) and 2.34
(1.79–13.37), respectively. The genotype analysis of the +1664 C/
T between SARS patients and control A group yielded different
result with those between patients and control B group, when the
control B group were compared, no difference of the genotype
distribution can be detected. Genotype frequencies of +705 A/G,
+1158T/C or +1196 G/C SNPs were not significantly different
between SARS patients and each of the two control groups.
Association between genotype frequencies of the 4 SNPs
and the severity of SARS
SARS patients were then divided into two subgroups according
to the severity of the disease: advanced subgroup (i.e., patients with
moderate or advanced lung disease) and mild subgroup. Multiple
regression models were re-established for each SNP, with age, sex
and the source of infection hospital as covariates. Association with
the severity of SARS infection was then estimated by comparing
the genotype frequencies and allele frequencies of all the SNPs
between the two groups of SARS patients. The final model
building disclosedprominentassociations between advanced disease
with carrying +1664 C/T (CT) and (TT) genotype (P=0.037).
However, this was found not to be significant after Nyholt
correction was applied to the analysis. Again, there were no
significant differences in the genotype and allele distributions of the
+705 A/G , +1158T/C or +1196 G/C SNPs between those with
mild disease and those with advanced disease (data not shown).
Haplotype analysis
Pairwise linkage disequilibrium (LD) analysis of the four SNPs
showed strong LD among +705 A/G, +1158T/C and +1196G/C








Ethnic (Han %) 100 100 100
Sex (male %) 32.5 46.7 71.0
Age (mean6SD) 33.1611.7 31.667.0 28.4611.8
Health care workers (%) 83 (72%) 110 (78%) 0 (0%)
Comorbidity (%) 10 (8.7%) 13 (9.2%) 10 (6.5%)
doi:10.1371/journal.pone.0002183.t001
Table 2. Allele frequencies of the IL-12 RB1 705A/G, 1158T/C, 1196G/C and 1664 C/T SNPs in SARS patients and controls
SNPs SARS (n=115) Control A (n=141) Control B (n=155) OR
a (95% CI) P value
a OR
b (95% CI) P value
b
+705A/G
A 131 (64.2) 137 (60.6) 186 (61.6) 1 1
G 73 (35.8) 89 (39.3) 116 (38.4) 0.87 (0.89–1.09) 0.224 0.91 (0.62–1.46) 0.171
+1158T/C
T 124 (64.6) 164 (65.6) 189 (63.0) 1 1
C 68 (35.4) 86 (34.4) 111 (37.0) 1.10 (0.39–1.70) 0.443 0.81 (0.56–2.41) 0.525
+1196G/C
G 139(62.6) 165(62.5) 190(63.3) 1 1
C 83(37.4) 99(37.5) 110 (36.7) 1.01 (0.79–1.71) 0.829 1.06 (0.51–1.31) 0.744
+1664C/T
C 133 (70.7) 213(80.7) 229(76.3) 1 1
T 55(29.3) 51(19.3) 71(23.7) 1.92 (1.11–6.06) 0.044 1.35 (1.06–1.70) 0.056
P-value and OR (95% CI) were calculated with the use of logistic regression models, adjusted with sex, age, comorbidity presence and infection source.
OR=Odds ratio; CI=confidence interval;
OR
a Patients VS Control A ; OR
b Patients VS Control B.
P value
a Patients VS Control A ; P value
b Patients VS Control B.
doi:10.1371/journal.pone.0002183.t002
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and one of the other three SNPs (D9=0.64–0.81), thus revealing
two common haplotypes (A-T-G-C (705-1158-1196-1664) and
G-C-C-T). To investigate if a particular haplotype constituted by
these SNPs was associated with the disease, haplotype frequencies
were estimated and association analysis was performed using
multiple logistic regression with age, sex and infection source being
the covariants. As shown in Table 4, the frequency of GCCT
haplotype in SARS patients (26.6%) was significantly increased
when compared to the control A group (11.1%), but when
compared to the control B group, the proportions of this haplotype
in the two groups were not different (26.6% in SARS patients vs.
22.3% in controls).
Discussion
IL-12R has previously been reported to be associated with
infectious diseases such as tuberculosis, hepatitis B virus infection,
and parvovirus infection [22–24], revealing its potential role of
function in host defense against microbial infections. We
genotyped 4 SNPs (+705A/G, +1158T/C , +1196G/C and
+1664 C/T) that have been alleged to cause missense mutations of
the IL-12 RB1 gene in SARS patients , close contacts and healthy
controls. These four SNPs (one novel) have been confirmed to
cause missense variants in the extracellular coding sequence of the
IL12RB1gene. These four SNPs lie within 6.2-kb span of genomic
DNA on chromosome 19p13.1. It is suggested that one or more of
Table 3. Genotype frequencies of IL-12 RB1 705A/G, 1158T/C, 1196G/C and 1664 C/T SNPs in SARS patients and controls groups
SNP SARS (n=115) Control A (n=141 ) Control B (n=155 ) OR
a(95% CI) P value
a OR
b (95% CI) P value
b
+A705G
AA 41 (40.2) 43(38.1) 59(39.1) 1 1
G A 49(48.0) 51(45.1) 68(45.0) 1.26 (0.20–1.05) 0.171 1.17 (0.95–4.91) 0.223
GG 12 (11.8) 19(16.8) 24(15.9) 0.76 (0.32–2.90) 0.082 0.64 (0.35–3.14) 0.194
+T1158C
TT 40 (41.7) 56(44.8) 59(39.3) 1 1
TC 44 (45.8) 52(41.6) 71(47.3) 1.29 (0.94–3.44) 0.105 0.90 (0.53–2.68) 0.137
CC 12 (12.5) 17 (13.6) 20(13.3) 0.71 (0.39–3.97) 0.219 0.84 (0.44–5.01) 0.166
+G1196C
GG 44 (39.6) 53(40.2) 59 (39.3) 1 1
GC 52 (46.8) 59(44.7) 72(48.0) 1.19 (0.71–3.07) 0.712 0.85 (0.25–6.10) 0.221
CC 15(13.5) 20(15.2) 19(12.7) 0.86 (0.74–3.83) 0.328 1.13 (0.39–6.95) 0.417
+C1664T
CC 47(50.0) 87(65.9) 88(58.7) 1 1
CT 39(41.5) 39(29.5) 52(34.7) 2.09 (1.90–7.16)
* 0.020
* 1.45 (1.16–2.78) 0.047
TT 8(8.5) 6(4.5) 10 (6.7) 2.34 (1.79–13.37)
* 0.022
* 1.47 (0.26–2.26) 0.060
P-value and OR (95% CI) were calculated with the use of logistic regression models, adjusted with sex, age, comorbidity presence and infection source.
OR=Odds ratio; CI=confidence interval;
OR
a Patients VS Control A ; OR
b Patients VS Control B.
P value
a Patients VS Control A ; P value
b Patients VS Control B.
*Significant P value after correction by Nyholt method
doi:10.1371/journal.pone.0002183.t003
Table 4. Estimated frequencies of haplotypes constituted by 705A/G, 1158T/C, 1196G/C and 1664 C/T SNPs of IL-12 RB1 in SARS
patients and controls
Haplotype SARS patients N(%) Control A N (%) Control B N (%) OR
a (95% CI) P value
a OR
b (95% CI) P value
b
ATGC 111 (59.0) 131(58.0) 182(60.7) 1 1
GCCT 50 (26.6 ) 25(11.1) 67(22.3) 2.31 (1.72–8.47)
* 0.011
* 1.14 (0.81–3.10) 0.443
GCCC 15(7.9) 52(23.0) 28(9.3) 0.29 (0.07–0.63)
* 0.017
* 0.90 (0.13–1.97) 0.602
Others
c 12 (6.4) 18 (8.0) 23(7.7) 0.76 (0.39–2.01) 0.314 0.92 (0.44–4.19) 0.580
P-value and OR (95% CI) were calculated with the use of logistic regression models, adjusted with sex, age, comorbidity presence and infection source.
OR=Odds ratio; CI=confidence interval;
aOR of Patients VS ControlA ;
bOR of Patients VS Control B.
cHaplotypes with frequencies ,5%.
*Significant P value after correction by Nyholt method
doi:10.1371/journal.pone.0002183.t004
IL12 and SARS
PLoS ONE | www.plosone.org 4 May 2008 | Volume 3 | Issue 5 | e2183the four missense variants could affect the quality (or quantity) of
the gene products and cause mild functional impairment in the
receptor’s responsiveness to IL-12 [25]. The results show that
individuals with 1664 C/T (CT) and (TT) genotype were at
increased risk of susceptibility to SARS infection. When only
severe patients were considered, the significance disappeared, in
comparison with the mild patients. We also estimated the
frequencies of IL-12 RB1 haplotypes, which composed of 4
polymorphic alleles, and identified risk haplotype (GCCT) that
might confer genetic susceptibility to SARS infection. In
agreement with this finding, the +1664 C/T (T) allele was among
the risk haplotypes GCCT, whereas the alternative C allele was
among the protective haplotype (GCCC). These findings support
the association between IL12B1 polymorphism and SARS
infection, but not necessary the disease outcome in Chinese
population.
It is interesting to note that these associations only exist when
close contacts were used as a control group. When healthy blood
donors were used as controls, no association could be detected. We
reasoned that genetic difference between the two control groups
might partly account for the distinct observations with regard to
SARS susceptibility, i.e. close contacts might be more immuno-
genetically resistant to SARS infection than healthy controls. In
this case, close contacts might serve as more suitable controls
healthy individuals, who had never been exposed to SARS-CoV.
It’s as well intriguing that the pattern of polymorphism in +1664
C/T in SARS patients deviated slightly from Hardy-Weinberg
equilibrium. As noted in the previous study[26], detection of HW
disequilibrium at SNP loci in the case sample could be an indicator
that a disease/susceptibility gene is within the region. There are
also other possibilities indicated, like that a pseudo-SNP is present,
DNA contamination, or a genotyping error, however, these latter
possibilities are unlikely since we have duplicated the genotyping
assay for all the samples with ambiguous results through
sequencing. This also can be argued from the observed perfect
adherence to Hardy-Weinberg disequilibrium from control group.
The chance of subgroup is minor, since all the subjects were
Chinese Han population without consanguineous relationship.
Taken together, we suggested this deviation was from the
correlation between genetic variant and disease, instead of false
association.
SARS pathogenesis is less well understood, yet it is a vital issue
in the disease management. It has been suggested that genetic
variations of the host and/or the virus may account for the
individual difference in the severity of the disease. Studies have
addressed some of the host genes that might play a role in disease
development [5,7]. However, all of the available studies have
failed to take viral factor(s) into consideration. These studies thus
cannot exclude the possible false association caused by the
differentiated viral adaption in humans. The SARS patients in
the current study were mostly health care workers in two SARS-
designated hospitals. Epidemiological investigations have clearly
defined detailed transmission among those patients, showing each
of the group came from one super spread chain arising from one
infection source. In the multiple logistic analysis, we used the
infection source as one of the covariants, and by doing so, we
could technically exclude the potential confounding effect that
might be caused by viral factor(s). Advanced age and presence of
comorbidity are other two factors that might influence the disease
susceptibility[3,4], which were excluded from potential confound-
ing by multiple variants analysis.
It should be mentioned not all of the subjects were genotyped
due to the inadequacy of DNA samples. Especially for the
+C1664T SNP, different percentages of genotypes were missing
from SARS, Control A, and Control B groups (18.2%, 6.4%
and 3.2% respectively). One can reasonably argue there was
another SNP that accounted for the increased fraction of
subjects without the defined genotypes in the SARS patient
group. It can also be argued that the significant SNPs actually
are not functional variants of the IL-12RB1 protein, but instead
it is presumably in linkage disequilibrium with a potential
functional variant(s) in other loci of the gene. Presently 15 coding,
nonsynonymous SNPS are listed in the Entrez database
dbSNP, out of a total of 274 known human SNPs for IL12RB1,
however, the genotyping for other SNPs in small group of
the current population showed MAF (minor allele frequency)
of less than 5% (unpublished data). We thus propose the lack
of a complete analysis of the SNPS in this gene can pose no
severe damage to the study. Still we could not formally exclude
possible additional causal variation(s) elsewhere in the gene.
The sequencing of the exon and the promoter regions of the
IL12RB1 gene from the SARS patient cohort could be helpful in
identifying other SNPs which could alter the gene expression level.
It would also be warranted to examine whether the same
association is observed in other ethnic groups. On the other
hand, a relatively small sample size inevitably resulted in
limitations of the power to detect significant association in disease
outcome. As such, the negative results on SNPs for disease
outcome revealed in this study do not necessarily exclude their
association with SARS.
In one previous study, marked elevation of IL-12 in plasma of
SARS patients had been observed for at least 2 weeks after disease
onset[27], Since IL-12 can induce the production of IFN-c and
other Th1 cytokines with suppression of the Th2 pathway
[28,29].the observed early elevation of IL-12 could be causative
of the SARS-CoV-induced activation of Th1 cells and NK cells,
release of chemokines such as IL-8, and results in pulmonary
inflammation [30]. One could then hypothesize that decreased
IL-12R activity might predispose to infection but protect from
severe disease manifestations. However, the data presented
here appear to suggest that IL-12R activity is required for
protection from severe disease, although the association between
genetic polymorphisms and severe disease was no longer
significant after multiple test correction was applied to the analysis.
Therefore the actual role of IL12 in the protection from or
susceptibility to severe disease still need more evidence from
animal experiments.
In summary, our data support the association between IL-12
RB1 polymorphism and SARS. These genetic variations might
predispose individuals to SARS infection by diminishing receptor
responsiveness to IL-12, leading to partial dysfunction of
interferon-c-mediated immunity. Further genetic and biologic
studies of these genetic variants could also render valuable insights
into SARS susceptibility and pathogenesis.
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